Cord Blood Stem Cells for Knee Osteoarthritis: The 2026 CARTISTEM Milestones, Explained

Three milestones in one year

MEDIPOST, a South Korean company, moved CARTISTEM through three big steps in 2026. In May the company announced a Japan Phase 3 trial met all primary and secondary endpoints. In June the FDA agreed that a single U.S. pivotal study, supported by earlier data, could underpin a planned U.S. approval filing. And in July the first U.S. participant was treated in that pivotal trial. Each step is real progress. Read together, they describe a therapy getting closer to a formal FDA decision, not one that is approved for sale.

“In 2026 CARTISTEM met all primary and secondary endpoints in its Japan Phase 3 trial, secured FDA agreement on a single U.S. pivotal study strategy, and treated the first U.S. participant in that trial. It remains an investigational therapy and is not FDA-approved for knee osteoarthritis.”

What CARTISTEM actually is

CARTISTEM is a human umbilical cord blood-derived mesenchymal stem cell therapy. Each dose contains roughly 7.5 million donated cord blood stem cells mixed into a hyaluronic acid gel, and it is surgically implanted into a knee cartilage defect rather than injected. It has been approved in South Korea since 2012, where more than 36,000 patients have been treated. That long real-world track record is part of why regulators in Japan and the United States are willing to consider it.

What the Japan Phase 3 trial showed

The Japan trial randomized 130 patients with moderate knee osteoarthritis across 13 sites. At 52 weeks it met both co-primary endpoints: improvements in WOMAC scores, the standard measure of pain and function, and in ICRS cartilage regeneration grade, a readout of cartilage appearance on imaging, both versus a hyaluronic acid control. MEDIPOST reported the safety profile as favorable, with serious adverse events judged unrelated to the product.

The FDA pathway: one pivotal study

In June 2026 the FDA agreed that a single U.S. pivotal Phase 3 trial, supported by the earlier Korean and Japanese Phase 3 data plus a roughly 550-patient Korean real-world evidence set, could support a planned Biologics License Application, or BLA. That agreement allowed MEDIPOST to run a U.S. trial of about 300 patients instead of a larger program. A BLA is the FDA pathway that could eventually make CARTISTEM an approved therapy in the United States. It has not happened yet.

First U.S. patient treated

In early July 2026 MEDIPOST treated the first U.S. participant in the randomized, double-blind U.S. Phase 3 trial for adults with symptomatic knee osteoarthritis and cartilage defects. The first procedure took place at Orthopedic Centers of Colorado, with Dr. Brian Cole, head of the Cartilage Research and Restoration Center at Rush University Medical Center, serving as a national lead investigator. A few later news roundups reported the milestone as a September event; the company's own announcements date the first treatment to July 2026.

What this does and does not change for patients

• CARTISTEM is not FDA-approved. Enrollment in the U.S. trial is happening under an investigational protocol, not as a marketed treatment.
• You cannot buy a CARTISTEM injection at a clinic. If a clinic claims to offer 'CARTISTEM' for sale, that claim does not match the public record.
• A positive Phase 3 result is promising but not final. The FDA will weigh the U.S. pivotal trial and the totality of evidence before any approval decision.
• This milestone concerns one specific product for knee osteoarthritis. It does not change the FDA status of any stem cell product for shoulders, hips, tendons, or wellness.
• No stem cell product is FDA-approved for osteoarthritis of any joint in the United States as of October 2026.

How this relates to the therapy at Aloha Stem Cell

Aloha Stem Cell does not offer CARTISTEM or any cord blood-derived product. The therapies we provide use your own cells and platelets, collected and prepared in the clinic, for joint and soft tissue support. That is a different category from an investigational allogeneic product, and we are direct about the difference. When a headline about a trial like this one appears, the honest question is always the same: is this a registered study, or something being sold as a treatment?